{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:54:56Z","timestamp":1792756496294,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Huntington\u2019s disease (HD) is a neurodegenerative disorder that manifests with movement dysfunction. The expression of mutant Huntingtin (mHTT) disrupts the functions of brain cells. Galectin-3 (Gal3) is a lectin that has not been extensively explored in brain diseases. Herein, we showed that the plasma Gal3 levels of HD patients and mice correlated with disease severity. Moreover, brain Gal3 levels were higher in patients and mice with HD than those in controls. The up-regulation of Gal3 in HD mice occurred before motor impairment, and its level remained high in microglia throughout disease progression. The cell-autonomous up-regulated Gal3 formed puncta in damaged lysosomes and contributed to inflammation through NF\u03baB- and NLRP3 inflammasome-dependent pathways. Knockdown of Gal3 suppressed inflammation, reduced mHTT aggregation, restored neuronal DARPP32 levels, ameliorated motor dysfunction, and increased survival in HD mice. Thus, suppression of Gal3 ameliorates microglia-mediated pathogenesis, which suggests that Gal3 is a novel druggable target for HD.<\/jats:p>","DOI":"10.1038\/s41467-019-11441-0","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T07:19:54Z","timestamp":1564730394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington\u2019s disease"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7028-3873","authenticated-orcid":false,"given":"Jian Jing","family":"Siew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-3391","authenticated-orcid":false,"given":"Hung-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-7153","authenticated-orcid":false,"given":"Bing-Wen","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Ru","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-7158","authenticated-orcid":false,"given":"Ching-Pang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-1001","authenticated-orcid":false,"given":"Fu-Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5842-5429","authenticated-orcid":false,"given":"Yijuang","family":"Chern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"11441_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"The Huntington\u2019s Disease Collaborative Research Group","year":"1993","unstructured":"The Huntington\u2019s Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes.Cell 72, 971\u2013983 (1993).","journal-title":"Cell"},{"key":"11441_CR2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1083\/jcb.200508072","volume":"171","author":"JY Shin","year":"2005","unstructured":"Shin, J. Y. et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 171, 1001\u20131012 (2005).","journal-title":"J. Cell Biol."},{"key":"11441_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.neubiorev.2013.01.022","volume":"37","author":"N Georgiou-Karistianis","year":"2013","unstructured":"Georgiou-Karistianis, N., Scahill, R., Tabrizi, S. J., Squitieri, F. & Aylward, E. Structural MRI in Huntington\u2019s disease and recommendations for its potential use in clinical trials. Neurosci. Biobehav. Rev. 37, 480\u2013490 (2013).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"11441_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.tibs.2013.05.003","volume":"38","author":"J Labbadia","year":"2013","unstructured":"Labbadia, J. & Morimoto, R. I. Huntington\u2019s disease: underlying molecular mechanisms and emerging concepts. Trends Biochem. Sci. 38, 378\u2013385 (2013).","journal-title":"Trends Biochem. Sci."},{"key":"11441_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrn3570","volume":"14","author":"MA Pouladi","year":"2013","unstructured":"Pouladi, M. A., Morton, A. J. & Hayden, M. R. Choosing an animal model for the study of Huntington\u2019s disease. Nat. Rev. Neurosci. 14, 708\u2013721 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"11441_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-160196","volume":"5","author":"LM Byrne","year":"2016","unstructured":"Byrne, L. M. & Wild, E. J. Cerebrospinal fluid biomarkers for Huntington\u2019s disease. J. Huntingt. Dis. 5, 1\u201313 (2016).","journal-title":"J. Huntingt. Dis."},{"key":"11441_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(11)70070-9","volume":"10","author":"DW Weir","year":"2011","unstructured":"Weir, D. W., Sturrock, A. & Leavitt, B. R. Development of biomarkers for Huntington\u2019s disease. Lancet Neurol. 10, 573\u2013590 (2011).","journal-title":"Lancet Neurol."},{"key":"11441_CR8","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bjorkqvist","year":"2008","unstructured":"Bjorkqvist, M. et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease. J. Exp. Med. 205, 1869\u20131877 (2008).","journal-title":"J. Exp. Med."},{"key":"11441_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/13550280290100969","volume":"8","author":"PL McGeer","year":"2002","unstructured":"McGeer, P. L. & McGeer, E. G. Local neuroinflammation and the progression of Alzheimer\u2019s disease. J. Neurovirol. 8, 529\u2013538 (2002).","journal-title":"J. Neurovirol."},{"key":"11441_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.nbd.2011.01.002","volume":"42","author":"M Sta","year":"2011","unstructured":"Sta, M. et al. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol. Dis. 42, 211\u2013220 (2011).","journal-title":"Neurobiol. Dis."},{"key":"11441_CR11","doi-asserted-by":"publisher","first-page":"9275","DOI":"10.1523\/JNEUROSCI.2614-05.2005","volume":"25","author":"C Cunningham","year":"2005","unstructured":"Cunningham, C., Wilcockson, D. C., Campion, S., Lunnon, K. & Perry, V. H. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 25, 9275\u20139284 (2005).","journal-title":"J. Neurosci."},{"key":"11441_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nn.3668","volume":"17","author":"A Crotti","year":"2014","unstructured":"Crotti, A. et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci. 17, 513\u2013521 (2014).","journal-title":"Nat. Neurosci."},{"key":"11441_CR13","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/hmg\/ddt036","volume":"22","author":"HY Hsiao","year":"2013","unstructured":"Hsiao, H. Y., Chen, Y. C., Chen, H. M., Tu, P. H. & Chern, Y. A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington\u2019s disease. Hum. Mol. Genet. 22, 1826\u20131842 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"11441_CR14","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1093\/hmg\/ddu151","volume":"23","author":"HY Hsiao","year":"2014","unstructured":"Hsiao, H. Y. et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington\u2019s disease. Hum. Mol. Genet. 23, 4328\u20134344 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"11441_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrc1527","volume":"5","author":"FT Liu","year":"2005","unstructured":"Liu, F. T. & Rabinovich, G. A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29\u201341 (2005).","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"11441_CR16","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.celrep.2015.02.012","volume":"10","author":"Miguel\u00a0Angel Burguillos","year":"2015","unstructured":"Burguillos, M. A. et al. Microglia-secreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep.\u00a010,\u00a01626\u20131638\u00a0(2015).","journal-title":"Cell Reports"},{"key":"11441_CR17","doi-asserted-by":"publisher","first-page":"10383","DOI":"10.1523\/JNEUROSCI.1498-12.2012","volume":"32","author":"M Lalancette-Hebert","year":"2012","unstructured":"Lalancette-Hebert, M. et al. Galectin-3 is required for resident microglia activation and proliferation in response to ischemic injury. J. Neurosci. 32, 10383\u201310395 (2012).","journal-title":"J. Neurosci."},{"key":"11441_CR18","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.4049\/jimmunol.182.2.1167","volume":"182","author":"HR Jiang","year":"2009","unstructured":"Jiang, H. R. et al. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J. Immunol. 182, 1167\u20131173 (2009).","journal-title":"J. Immunol."},{"key":"11441_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/brb3.75","volume":"2","author":"BJ Lerman","year":"2012","unstructured":"Lerman, B. J. et al. Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav. 2, 563\u2013575 (2012).","journal-title":"Brain Behav."},{"key":"11441_CR20","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1074\/jbc.M107668200","volume":"277","author":"T Yoshii","year":"2002","unstructured":"Yoshii, T. et al. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J. Biol. Chem. 277, 6852\u20136857 (2002).","journal-title":"J. Biol. Chem."},{"key":"11441_CR21","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1074\/jbc.M604506200","volume":"282","author":"J Nieminen","year":"2007","unstructured":"Nieminen, J., Kuno, A., Hirabayashi, J. & Sato, S. Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J. Biol. Chem. 282, 1374\u20131383 (2007).","journal-title":"J. Biol. Chem."},{"key":"11441_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00401-017-1722-x","volume":"134","author":"WP Flavin","year":"2017","unstructured":"Flavin, W. P. et al. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol. 134, 629\u2013653 (2017).","journal-title":"Acta Neuropathol."},{"key":"11441_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13024-016-0092-5","volume":"11","author":"ED Nekrasov","year":"2016","unstructured":"Nekrasov, E. D. et al. Manifestation of Huntington\u2019s disease pathology in human induced pluripotent stem cell-derived neurons. Mol. Neurodegener. 11, 27 (2016).","journal-title":"Mol. Neurodegener."},{"key":"11441_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1177\/1533317513495107","volume":"30","author":"X Wang","year":"2015","unstructured":"Wang, X., Zhang, S., Lin, F., Chu, W. & Yue, S. Elevated galectin-3 levels in the serum of patients with Alzheimer\u2019s disease. Am. J. Alzheimers Dis. Other Demen. 30, 729\u2013732 (2015).","journal-title":"Am. J. Alzheimers Dis. Other Demen."},{"key":"11441_CR25","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1093\/hmg\/dds193","volume":"21","author":"CV Cluzeau","year":"2012","unstructured":"Cluzeau, C. V. et al. Microarray expression analysis and identification of serum biomarkers for Niemann\u2013Pick disease, type C1. Hum. Mol. Genet. 21, 3632\u20133646 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"11441_CR26","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.4103\/0366-6999.194656","volume":"129","author":"J Yan","year":"2016","unstructured":"Yan, J. et al. Increased expressions of plasma galectin-3 in patients with amyotrophic lateral sclerosis. Chin. Med. J. 129, 2797\u20132803 (2016).","journal-title":"Chin. Med. J."},{"key":"11441_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3174\/ajnr.A1891","volume":"31","author":"ML Mandelli","year":"2010","unstructured":"Mandelli, M. L. et al. Decreased diffusivity in the caudate nucleus of presymptomatic huntington disease gene carriers: which explanation? Am. J. Neuroradiol. 31, 706\u2013710 (2010).","journal-title":"Am. J. Neuroradiol."},{"key":"11441_CR28","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/mds.25984","volume":"29","author":"EM Rees","year":"2014","unstructured":"Rees, E. M. et al. Cerebellar abnormalities in Huntington\u2019s disease: a role in motor and psychiatric impairment? Mov. Disord. 29, 1648\u20131654 (2014).","journal-title":"Mov. Disord."},{"key":"11441_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1750-3639.2012.00629.x","volume":"23","author":"U Rub","year":"2013","unstructured":"Rub, U. et al. Degeneration of the cerebellum in Huntington\u2019s disease (HD): possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. Brain Pathol. 23, 165\u2013177 (2013).","journal-title":"Brain Pathol."},{"key":"11441_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493\u2013506 (1996).","journal-title":"Cell"},{"key":"11441_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1042\/bj20031300","volume":"380","author":"L Liu","year":"2004","unstructured":"Liu, L., Sakai, T., Sano, N. & Fukui, K. Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling. Biochem. J. 380, 31\u201341 (2004).","journal-title":"Biochem. J."},{"key":"11441_CR32","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/labinvest.2015.77","volume":"95","author":"N Serizawa","year":"2015","unstructured":"Serizawa, N. et al. Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. Lab. Invest. 95, 1145\u20131156 (2015).","journal-title":"Lab. Invest."},{"key":"11441_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep29457","volume":"6","author":"TJ Hsieh","year":"2016","unstructured":"Hsieh, T. J. et al. Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors. Sci. Rep. 6, 29457 (2016).","journal-title":"Sci. Rep."},{"key":"11441_CR34","first-page":"48","volume":"8","author":"SY Wu","year":"2017","unstructured":"Wu, S. Y. et al. Cell intrinsic galectin-3 attenuates neutrophil ROS-dependent killing of Candida by modulating CR3 downstream Syk activation. Front. Immunol. 8, 48 (2017).","journal-title":"Front. Immunol."},{"key":"11441_CR35","doi-asserted-by":"publisher","first-page":"778","DOI":"10.4049\/jimmunol.176.2.778","volume":"176","author":"BN Stillman","year":"2006","unstructured":"Stillman, B. N. et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J. Immunol. 176, 778\u2013789 (2006).","journal-title":"J. Immunol."},{"key":"11441_CR36","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1523\/JNEUROSCI.5575-11.2012","volume":"32","author":"M Usenovic","year":"2012","unstructured":"Usenovic, M., Tresse, E., Mazzulli, J. R., Taylor, J. P. & Krainc, D. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J. Neurosci. 32, 4240\u20134246 (2012).","journal-title":"J. Neurosci."},{"key":"11441_CR37","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/ecco-jcc\/jjw013","volume":"10","author":"B Simovic Markovic","year":"2016","unstructured":"Simovic Markovic, B. et al. Galectin-3 plays an important pro-inflammatory role in the induction phase of acute colitis by promoting activation of NLRP3 inflammasome and production of IL-1beta in macrophages. J. Crohn\u2019s Colitis 10, 593\u2013606 (2016).","journal-title":"J. Crohn\u2019s Colitis"},{"key":"11441_CR38","doi-asserted-by":"publisher","first-page":"C83","DOI":"10.1152\/ajpcell.00298.2015","volume":"311","author":"MA Katsnelson","year":"2016","unstructured":"Katsnelson, M. A., Lozada-Soto, K. M., Russo, H. M., Miller, B. A. & Dubyak, G. R. NLRP3 inflammasome signaling is activated by low-level lysosome disruption but inhibited by extensive lysosome disruption: roles for K+ efflux and Ca2+ influx. Am. J. Physiol. Cell Physiol. 311, C83\u2013C100 (2016).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"11441_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248\u2013255 (2015).","journal-title":"Nat. Med."},{"key":"11441_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nm985","volume":"10","author":"M Tanaka","year":"2004","unstructured":"Tanaka, M. et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10, 148\u2013154 (2004).","journal-title":"Nat. Med."},{"key":"11441_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nm.2558","volume":"18","author":"M Jiang","year":"2011","unstructured":"Jiang, M. et al. Neuroprotective role of Sirt1 in mammalian models of Huntington\u2019s disease through activation of multiple Sirt1 targets. Nat. Med. 18, 153\u2013158 (2011).","journal-title":"Nat. Med."},{"key":"11441_CR42","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/mds.25159","volume":"27","author":"Z Guo","year":"2012","unstructured":"Guo, Z. et al. Striatal neuronal loss correlates with clinical motor impairment in Huntington\u2019s disease. Mov. Disord. 27, 1379\u20131386 (2012).","journal-title":"Mov. Disord."},{"key":"11441_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.bbrc.2007.05.163","volume":"359","author":"SW Mok","year":"2007","unstructured":"Mok, S. W. et al. Role of galectin-3 in prion infections of the CNS. Biochem. Biophys. Res. Commun. 359, 672\u2013678 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"11441_CR44","doi-asserted-by":"publisher","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","volume":"34","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929\u201311947 (2014).","journal-title":"J. Neurosci."},{"key":"11441_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11357-017-9965-y","volume":"39","author":"E Shobin","year":"2017","unstructured":"Shobin, E. et al. Microglia activation and phagocytosis: relationship with aging and cognitive impairment in the rhesus monkey. GeroScience 39, 199\u2013220 (2017).","journal-title":"GeroScience"},{"key":"11441_CR46","first-page":"1661","volume":"148","author":"DK Hsu","year":"1996","unstructured":"Hsu, D. K., Hammes, S. R., Kuwabara, I., Greene, W. C. & Liu, F. T. Human T lymphotropic virus-I infection of human T lymphocytes induces expression of the beta-galactoside-binding lectin, galectin-3. Am. J. Pathol. 148, 1661\u20131670 (1996).","journal-title":"Am. J. Pathol."},{"key":"11441_CR47","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/S0002-9440(10)64975-9","volume":"156","author":"DK Hsu","year":"2000","unstructured":"Hsu, D. K. et al. Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am. J. Pathol. 156, 1073\u20131083 (2000).","journal-title":"Am. J. Pathol."},{"key":"11441_CR48","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1182\/blood-2009-10-251660","volume":"115","author":"MJ Streetly","year":"2010","unstructured":"Streetly, M. J. et al. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood 115, 3939\u20133948 (2010).","journal-title":"Blood"},{"key":"11441_CR49","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1523\/JNEUROSCI.0116-08.2008","volume":"28","author":"SY Chou","year":"2008","unstructured":"Chou, S. Y. et al. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5\/RANTES) by astrocytes. J. Neurosci. 28, 3277\u20133290 (2008).","journal-title":"J. Neurosci."},{"key":"11441_CR50","doi-asserted-by":"publisher","first-page":"e62143","DOI":"10.1371\/journal.pone.0062143","volume":"8","author":"D Freeman","year":"2013","unstructured":"Freeman, D. et al. Alpha-synuclein induces lysosomal rupture and cathepsin dependent reactive oxygen species following endocytosis. PLoS ONE 8, e62143 (2013).","journal-title":"PLoS ONE"},{"key":"11441_CR51","doi-asserted-by":"publisher","first-page":"8574","DOI":"10.1073\/pnas.1702615114","volume":"114","author":"Y Yoshida","year":"2017","unstructured":"Yoshida, Y. et al. Ubiquitination of exposed glycoproteins by SCF(FBXO27) directs damaged lysosomes for autophagy. Proc. Natl Acad. Sci. USA 114, 8574\u20138579 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11441_CR52","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/(SICI)1097-0215(19980105)75:1<105::AID-IJC16>3.0.CO;2-F","volume":"75","author":"V Sarafian","year":"1998","unstructured":"Sarafian, V. et al. Expression of Lamp-1 and Lamp-2 and their interactions with galectin-3 in human tumor cells. Int J. Cancer 75, 105\u2013111 (1998).","journal-title":"Int J. Cancer"},{"key":"11441_CR53","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka, M. T. et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature 493, 674\u2013678 (2013).","journal-title":"Nature"},{"issue":"4","key":"11441_CR54","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ajpath.2017.12.014","volume":"188","author":"Yu-Jung Chen","year":"2018","unstructured":"Chen, Y. J. et al. Galectin-3 enhances avian H5N1 Influenza A virus-induced pulmonary inflammation by promoting NLRP3 inflammasome activation. Am. J. Pathol. 188, 1031\u20131042 (2018).","journal-title":"The American Journal of Pathology"},{"key":"11441_CR55","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.bbrc.2015.02.029","volume":"458","author":"SG Boaru","year":"2015","unstructured":"Boaru, S. G. et al. NLRP3 inflammasome expression is driven by NF-kappaB in cultured hepatocytes. Biochem Biophys. Res. Commun. 458, 700\u2013706 (2015).","journal-title":"Biochem Biophys. Res. Commun."},{"key":"11441_CR56","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1073\/pnas.1322831111","volume":"111","author":"A de Luca","year":"2014","unstructured":"de Luca, A. et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc. Natl Acad. Sci. USA 111, 3526\u20133531 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11441_CR57","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1309\/LM3JZKBDA7D4QFOC","volume":"45","author":"AA Alturfan","year":"2014","unstructured":"Alturfan, A. A. et al. Galectin-3 and plasma cytokines in patients with acute myocardial infarction. Lab. Med. 45, 336\u2013341 (2014).","journal-title":"Lab. Med."},{"key":"11441_CR58","doi-asserted-by":"publisher","first-page":"e003804","DOI":"10.1161\/CIRCHEARTFAILURE.116.003804","volume":"10","author":"C Besler","year":"2017","unstructured":"Besler, C. et al. Plasma and cardiac galectin-3 in patients with heart failure reflects both inflammation and fibrosis: implications for its use as a biomarker. Circ. Heart Fail. 10, e003804 (2017).","journal-title":"Circ. Heart Fail."},{"key":"11441_CR59","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00281-018-0676-y","volume":"40","author":"R Ramachandran","year":"2018","unstructured":"Ramachandran, R. Neurogenic inflammation and its role in migraine. Semin. Immunopathol. 40, 301\u2013314 (2018).","journal-title":"Semin. Immunopathol."},{"key":"11441_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0601-z","volume":"13","author":"T Minett","year":"2016","unstructured":"Minett, T. et al. Microglial immunophenotype in dementia with Alzheimer\u2019s pathology. J. Neuroinflamm. 13, 135 (2016).","journal-title":"J. Neuroinflamm."},{"key":"11441_CR61","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/brain\/awt355","volume":"137","author":"U Trager","year":"2014","unstructured":"Trager, U. et al. HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NFkappaB pathway dysregulation. Brain 137, 819\u2013833 (2014).","journal-title":"Brain"},{"key":"11441_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1365-2796.2011.02476.x","volume":"272","author":"RA de Boer","year":"2012","unstructured":"de Boer, R. A. et al. The fibrosis marker galectin-3 and outcome in the general population. J. Intern. Med. 272, 55\u201364 (2012).","journal-title":"J. Intern. Med."},{"key":"11441_CR63","doi-asserted-by":"publisher","first-page":"e9077","DOI":"10.1371\/journal.pone.0009077","volume":"5","author":"NI Wood","year":"2010","unstructured":"Wood, N. I. et al. Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington\u2019s disease. PLoS One 5, e9077 (2010).","journal-title":"PLoS One"},{"key":"11441_CR64","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1083\/jcb.201105010","volume":"194","author":"TC Ju","year":"2011","unstructured":"Ju, T. C. et al. Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington\u2019s disease. J. Cell Biol. 194, 209\u2013227 (2011).","journal-title":"J. Cell Biol."},{"key":"11441_CR65","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.1021\/bi952716q","volume":"35","author":"FT Liu","year":"1996","unstructured":"Liu, F. T. et al. Modulation of functional properties of galectin-3 by monoclonal antibodies binding to the non-lectin domains. Biochemistry 35, 6073\u20136079 (1996).","journal-title":"Biochemistry"},{"key":"11441_CR66","first-page":"1016","volume":"147","author":"FT Liu","year":"1995","unstructured":"Liu, F. T. et al. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am. J. Pathol. 147, 1016\u20131028 (1995).","journal-title":"Am. J. Pathol."},{"key":"11441_CR67","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1093\/hmg\/ddu151","volume":"23","author":"HY Hsiao","year":"2014","unstructured":"Hsiao, H. Y. et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington\u2019s disease. Hum. Mol. Genet. 23, 4328\u20134344 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"11441_CR68","doi-asserted-by":"publisher","first-page":"RRN1258","DOI":"10.1371\/currents.RRN1258","volume":"3","author":"M Orth","year":"2011","unstructured":"Orth, M. & Schwenke, C. Age-at-onset in Huntington disease. PLoS Curr. 3, RRN1258 (2011).","journal-title":"PLoS Curr."},{"key":"11441_CR69","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"11441_CR70","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group Unified Huntington\u2019s Disease Rating Scale: reliability and consistency.Mov. Disord. 11, 136\u2013142 (1996).","journal-title":"Mov. Disord."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11441-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11441-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11441-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T19:41:26Z","timestamp":1671219686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11441-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["11441"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-11441-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736337566.793567336","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"16 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3473"}}